DRUG AGING 润色咨询

DRUGS & AGING

出版年份：1991 年文章数：1635 投稿命中率： 开通期刊会员，数据随心看

出版周期：Monthly 自引率：4.9% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1089787, encodeId=82a11089e875b, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089788, encodeId=dbe51089e88a8, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919947, encodeId=34b191994e3e, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：临床药理<br>经验分享：写的基础药理实验类文章，12月31号投的，1月19号收到退稿，说是不收动物实验类的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e60d5455898, createdName=ms8000000720052443, createdTime=Tue Jan 26 09:57:04 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562567, encodeId=075f56256ede, content=投稿1个月，被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ff51707313, createdName=珉妮的马桶2c3ce65a, createdTime=Tue Oct 30 20:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=492340, encodeId=d328492340db, content=明年能不能冲到3分？大家谈谈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=330, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qupeter, createdTime=Wed Nov 28 16:24:00 CST 2012, time=2012-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=485054, encodeId=b1b948505446, content=处理稿件超慢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=339, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Oct 27 08:47:00 CST 2011, time=2011-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481123, encodeId=e40448112352, content=看涨哦，如果明天再升一升，有望突破3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=391, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:50:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]
    2021-12-27 msSSSSSD

    上传文章有什么要求？

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1089787, encodeId=82a11089e875b, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089788, encodeId=dbe51089e88a8, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919947, encodeId=34b191994e3e, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：临床药理<br>经验分享：写的基础药理实验类文章，12月31号投的，1月19号收到退稿，说是不收动物实验类的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e60d5455898, createdName=ms8000000720052443, createdTime=Tue Jan 26 09:57:04 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562567, encodeId=075f56256ede, content=投稿1个月，被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ff51707313, createdName=珉妮的马桶2c3ce65a, createdTime=Tue Oct 30 20:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=492340, encodeId=d328492340db, content=明年能不能冲到3分？大家谈谈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=330, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qupeter, createdTime=Wed Nov 28 16:24:00 CST 2012, time=2012-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=485054, encodeId=b1b948505446, content=处理稿件超慢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=339, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Oct 27 08:47:00 CST 2011, time=2011-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481123, encodeId=e40448112352, content=看涨哦，如果明天再升一升，有望突破3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=391, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:50:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]
    2021-12-27 ms6000000264964247

    如何判断两种药物之间是协同作用还是相加作用？

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=1089787, encodeId=82a11089e875b, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089788, encodeId=dbe51089e88a8, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919947, encodeId=34b191994e3e, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：临床药理<br>经验分享：写的基础药理实验类文章，12月31号投的，1月19号收到退稿，说是不收动物实验类的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e60d5455898, createdName=ms8000000720052443, createdTime=Tue Jan 26 09:57:04 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562567, encodeId=075f56256ede, content=投稿1个月，被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ff51707313, createdName=珉妮的马桶2c3ce65a, createdTime=Tue Oct 30 20:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=492340, encodeId=d328492340db, content=明年能不能冲到3分？大家谈谈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=330, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qupeter, createdTime=Wed Nov 28 16:24:00 CST 2012, time=2012-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=485054, encodeId=b1b948505446, content=处理稿件超慢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=339, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Oct 27 08:47:00 CST 2011, time=2011-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481123, encodeId=e40448112352, content=看涨哦，如果明天再升一升，有望突破3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=391, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:50:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]
    2021-01-26 ms8000000720052443

    审稿速度:1.0 | 投稿命中率:50.0
    偏重的研究方向：临床药理
    经验分享：写的基础药理实验类文章，12月31号投的，1月19号收到退稿，说是不收动物实验类的文章

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1089787, encodeId=82a11089e875b, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089788, encodeId=dbe51089e88a8, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919947, encodeId=34b191994e3e, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：临床药理<br>经验分享：写的基础药理实验类文章，12月31号投的，1月19号收到退稿，说是不收动物实验类的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e60d5455898, createdName=ms8000000720052443, createdTime=Tue Jan 26 09:57:04 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562567, encodeId=075f56256ede, content=投稿1个月，被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ff51707313, createdName=珉妮的马桶2c3ce65a, createdTime=Tue Oct 30 20:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=492340, encodeId=d328492340db, content=明年能不能冲到3分？大家谈谈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=330, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qupeter, createdTime=Wed Nov 28 16:24:00 CST 2012, time=2012-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=485054, encodeId=b1b948505446, content=处理稿件超慢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=339, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Oct 27 08:47:00 CST 2011, time=2011-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481123, encodeId=e40448112352, content=看涨哦，如果明天再升一升，有望突破3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=391, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:50:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]
    2018-10-30 珉妮的马桶2c3ce65a

    投稿1个月，被拒。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1089787, encodeId=82a11089e875b, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089788, encodeId=dbe51089e88a8, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919947, encodeId=34b191994e3e, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：临床药理<br>经验分享：写的基础药理实验类文章，12月31号投的，1月19号收到退稿，说是不收动物实验类的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e60d5455898, createdName=ms8000000720052443, createdTime=Tue Jan 26 09:57:04 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562567, encodeId=075f56256ede, content=投稿1个月，被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ff51707313, createdName=珉妮的马桶2c3ce65a, createdTime=Tue Oct 30 20:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=492340, encodeId=d328492340db, content=明年能不能冲到3分？大家谈谈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=330, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qupeter, createdTime=Wed Nov 28 16:24:00 CST 2012, time=2012-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=485054, encodeId=b1b948505446, content=处理稿件超慢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=339, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Oct 27 08:47:00 CST 2011, time=2011-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481123, encodeId=e40448112352, content=看涨哦，如果明天再升一升，有望突破3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=391, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:50:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]
    2012-11-28 qupeter

    明年能不能冲到3分？大家谈谈

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1089787, encodeId=82a11089e875b, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089788, encodeId=dbe51089e88a8, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919947, encodeId=34b191994e3e, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：临床药理<br>经验分享：写的基础药理实验类文章，12月31号投的，1月19号收到退稿，说是不收动物实验类的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e60d5455898, createdName=ms8000000720052443, createdTime=Tue Jan 26 09:57:04 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562567, encodeId=075f56256ede, content=投稿1个月，被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ff51707313, createdName=珉妮的马桶2c3ce65a, createdTime=Tue Oct 30 20:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=492340, encodeId=d328492340db, content=明年能不能冲到3分？大家谈谈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=330, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qupeter, createdTime=Wed Nov 28 16:24:00 CST 2012, time=2012-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=485054, encodeId=b1b948505446, content=处理稿件超慢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=339, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Oct 27 08:47:00 CST 2011, time=2011-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481123, encodeId=e40448112352, content=看涨哦，如果明天再升一升，有望突破3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=391, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:50:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]
    2011-10-27 匿名用户

    处理稿件超慢！

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1089787, encodeId=82a11089e875b, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089788, encodeId=dbe51089e88a8, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919947, encodeId=34b191994e3e, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：临床药理<br>经验分享：写的基础药理实验类文章，12月31号投的，1月19号收到退稿，说是不收动物实验类的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e60d5455898, createdName=ms8000000720052443, createdTime=Tue Jan 26 09:57:04 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562567, encodeId=075f56256ede, content=投稿1个月，被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ff51707313, createdName=珉妮的马桶2c3ce65a, createdTime=Tue Oct 30 20:28:00 CST 2018, time=2018-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=492340, encodeId=d328492340db, content=明年能不能冲到3分？大家谈谈, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=330, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qupeter, createdTime=Wed Nov 28 16:24:00 CST 2012, time=2012-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=485054, encodeId=b1b948505446, content=处理稿件超慢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=339, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Oct 27 08:47:00 CST 2011, time=2011-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=481123, encodeId=e40448112352, content=看涨哦，如果明天再升一升，有望突破3分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=391, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=medwu, createdTime=Wed Jun 29 15:50:00 CST 2011, time=2011-06-29, status=1, ipAttribution=)]
    2011-06-29 medwu

    看涨哦，如果明天再升一升，有望突破3分

    0

共9条页码: 1/1页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分